Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Step Therapy Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentHealthPartnersPolicy 26132

    2026 Medicare Part D Step Therapy Requirements

    Customize your policy alerts

    Sign up for HealthPartners Policy 26132 alerts

    Get alerted when Policy 26132 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step therapy requirements for selected HealthPartners Medicare Part D formulary products effective November 1, 2026. Providers must document prior use of specified prerequisite therapies before the affected Step 2 products may be covered.

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy 26132
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Next Review DateNot specified
    Key ActionDocument prior use of the required prerequisite therapy within the previous 12 months before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Step 2 product groups
    4Carbidopa-levodopa strengths
    3Tazarotene products
    12 monthsPrior-use lookback

    Step Therapy Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Carbidopa-levodopa extended-release Step 2

    Carbidopa-levodopa extended-release products are Step 2 and require the following prerequisite.

    Prior therapy: Prior use of carbidopa-levodopa immediate-release or extended-release tabletswithin the previous 12 months

    Required before coverage of the affected Step 2 extended-release capsules.

    Tazarotene Step 2

    Affected tazarotene products are Step 2 and require the following prerequisite.

    Prior therapy: Prior use of tazarotene 0.1% creamwithin the previous 12 months

    Required before coverage of the affected Step 2 tazarotene products.

    Documentation and Authorization Requirements

    Prior Authorization

    Prior Carbidopa-Levodopa Therapy Required

    Before coverage of the Step 2 carbidopa-levodopa extended-release capsules, document prior use of qualifying carbidopa-levodopa immediate-release or extended-release tablets.

    • Required prerequisite: carbidopa-levodopa immediate-release or extended-release tablets used within the previous 12 months.
    Prior Authorization

    Prior Tazarotene 0.1% Cream Required

    Before coverage of Step 2 tazarotene products, document prior use of tazarotene 0.1% topical cream.

    • Required prerequisite: tazarotene 0.1% cream used within the previous 12 months.
    Step Therapy

    Carbidopa-Levodopa Extended-Release: Step 2

    Carbidopa-levodopa extended-release capsules are subject to Step 2 therapy. Coverage requires documented prior use of qualifying carbidopa-levodopa tablet therapy.

    • CARBIDOPA ER 23.75 mg-LEVODOPA 95 mg extended-release capsule
    • CARBIDOPA ER 36.25 mg-LEVODOPA 145 mg extended-release capsule
    • CARBIDOPA ER 48.75 mg-LEVODOPA 195 mg extended-release capsule
    • CARBIDOPA ER 61.25 mg-LEVODOPA 245 mg extended-release capsule
    Step Therapy

    Tazarotene: Step 2

    Tazarotene Step 2 products require documented prior use of tazarotene 0.1% cream within the previous 12 months.

    • tazarotene 0.05% topical cream
    • tazarotene 0.05% topical gel
    • tazarotene 0.1% topical gel
    Documentation Required

    Document Prior Carbidopa-Levodopa Use

    For the carbidopa-levodopa extended-release request, submit documentation showing use of carbidopa-levodopa immediate-release or extended-release tablets during the previous 12 months.

    • Document the product and dates of qualifying tablet therapy when submitting the request.
    Documentation Required

    Document Prior Tazarotene Cream Use

    For the tazarotene Step 2 request, submit documentation showing use of tazarotene 0.1% cream during the previous 12 months.

    • Document the product and dates of qualifying cream therapy when submitting the request.
    Denial Risk

    Carbidopa-Levodopa Prerequisite Not Met

    Coverage for the carbidopa-levodopa extended-release Step 2 products may be denied if prior qualifying tablet therapy within the previous 12 months is not documented.

    • Qualifying therapy is carbidopa-levodopa immediate-release or extended-release tablets.
    Denial Risk

    Tazarotene Prerequisite Not Met

    Coverage for the tazarotene Step 2 products may be denied if prior tazarotene 0.1% cream use within the previous 12 months is not documented.

    • The required lookback period is the previous 12 months.

    Initial Authorization Criteria

    RYTARY/carbidopa-levodopa extended-release initial authorization

    Step 2 products require prior therapy.

    Carbidopa-levodopa prerequisite: Prior use of carbidopa-levodopa immediate-release or extended-release tabletswithin the previous 12 months

    Applies to the four listed carbidopa-levodopa extended-release capsule strengths.

    Tazarotene initial authorization

    Step 2 products require prior therapy.

    Tazarotene prerequisite: Prior use of tazarotene 0.1% creamwithin the previous 12 months

    Applies to the listed tazarotene 0.05% cream, 0.05% gel, and 0.1% gel products.

    Required Prerequisite Therapies

    Products affectedStepRequired prior therapyLookback period
    Carbidopa ER 23.75 mg-levodopa 95 mg extended-release capsule; carbidopa ER 36.25 mg-levodopa 145 mg extended-release capsule; carbidopa ER 48.75 mg-levodopa 195 mg extended-release capsule; carbidopa ER 61.25 mg-levodopa 245 mg extended-release capsuleStep 2Prior use of carbidopa-levodopa immediate-release or extended-release tabletsWithin the previous 12 months
    Products affectedStepRequired prior therapyLookback period
    Tazarotene 0.05% topical cream; tazarotene 0.05% topical gel; tazarotene 0.1% topical gelStep 2Prior use of tazarotene 0.1% creamWithin the previous 12 months
    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy 26132
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Next Review DateNot specified
    Key ActionDocument prior use of the required prerequisite therapy within the previous 12 months before requesting coverage.
    SourceLink
    On This Page
    Step Therapy Coverage CriteriaDocumentation and Authorization RequirementsInitial Authorization CriteriaRequired Prerequisite Therapies